Alliances
The three-way deal is focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer.
“We are Earth’s Tech Support,” declared Randall Kirk, Executive Chairman of the Board of Directors and former CEO of Intrexon. His company is one of the biggest developers of synthetic biology (or engineering biology) applications in therapeutics, agriculture and chemicals.
On Monday, the two companies forged a collaboration and license agreement that has the potential to be worth more than $450 million.
This year marked yet another series of interesting, exciting and occasionally puzzling stories coming out of the biopharma industry. Our breaking news writers, Alex Keown and Mark Terry, picked their top 10 stories of the year.
Pfizer handed over $10 million in upfront money and dangled a potential $240 million more if the program hits certain development and sales milestones.
Sarepta Therapeutics and Roche inked a licensing deal that gives Roche exclusive commercial rights to SRP-9001, Sarepta’s investigation gene therapy for Duchenne muscular dystrophy, outside the U.S.
Less than a month after snagging approval for a first-of-its-kind sickle cell disease treatment, Global Blood Therapeutics (GBT) is already looking at next-generation measures to tackle the disorder, as well as other diseases of the blood such as beta thalassemia.
Evotec SE announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi.
Vaccitech Ltd announced that its strategic collaboration with the Ludwig Institute for Cancer Research, Vaccitech Oncology Limited, has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer.
The two companies will pair up to advance Turnstone’s lead program, RIVAL-01, in multiple cancer studies and will also work together to identify additional novel product candidates based on Turnstone’s vaccinia virus platform for future independent development.
PRESS RELEASES